Overview

Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer

Status:
Active, not recruiting

Trial end date:
2020-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find out whether patients with cervical cancer treated with IMRT have less side effects with equal cancer control compared to standard radiation techniques. With standard radiation techniques, normal pelvic organs near the tumor receive radiation dose, which leads to side effects. IMRT is a new radiation technique that can reduce radiation dose to these organs and may reduce side effects. Compared to conventional RT techniques, the hypothesis is that IMRT will reduce acute hematologic and gastrointestinal toxicity for cervical cancer patients treated with concurrent cisplatin.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

University of California, San Diego

Collaborator:

National Cancer Institute (NCI)

Treatments:

Cisplatin